CRNX · NASDAQ · STOCK
Crinetics Pharmaceuticals (CRNX) Stock Analysis
$84.96
52W $32.30 – $85.01
64/100
$9.00B
-16.8
0.13
Is CRNX Bullish or Bearish?
Bullish.
Innellis AI committee rates Crinetics Pharmaceuticals, Inc. (CRNX) Buy with a composite score of 64/100
, based on 6 analysts with 50% agreement.
Last updated September 07, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +11.18 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -8.82 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- Revenue growing 2928.4% YoY -- genuine top-line momentum — Growth
- 3 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- ROE of only -44.2% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 91 -- overbought on the larger timeframe too — Technical
- No news coverage in the last 14 days -- limited independent confirmation either way — News
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 07, 2026
Overall Committee Score
64/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 9%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.5x prices in significant intangible value
Growth Analyst
bullish
83
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 2928.4% YoY -- genuine top-line momentum
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 90 is in overbought territory
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
48
/ 100 · Moderate confidence
News flow is mixed or quiet -- no strong signal either way right now
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 63.8 to 63.8.
Comparing 2026-09-06 to 2026-09-07 (1 day apart).
Technical Analysis
RSI (14)
90.0
Overbought
MACD Histogram
-0.858
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.81
Inside Bands
Price vs Moving Averages
EMA 9
$84.80
Above
EMA 21
$83.52
Above
EMA 50
$74.81
Above
EMA 200
$53.97
Above
Fundamental Analysis
Valuation
69
Growth
73
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-16.8×
P/B Ratio
7.52×
PEG Ratio
0.83
Dividend Yield
0.00%
52W High
$85.01
52W Low
$32.30
Quality & Growth
ROE
-4690.3%
ROA
-4097.9%
Gross Margin
9916.0%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.04
AI Fundamental Assessment
P/E ratio of -16.8 (inexpensive relative to a 15-40x range); Price-to-book of 7.5x; PEG ratio of 0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -46.9%; Return on assets of -41.0%; Net margin of -1189.9%; Gross margin of 99.2%; Current ratio of 15.57 (healthy short-term liquidity); Debt-to-equity of 0.04; Free cash flow per share is negative (-4.03); Most recent quarter beat estimates by 7.6%; 3 consecutive earnings beats; EPS growth accelerating (+4.7% -> +7.3% QoQ); Analyst estimates rising over recent quarters
Get the Full CRNX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →